share_log

康寧傑瑞製藥-B：翌日披露報表

ALPHAMAB-B: Next Day Disclosure Return

HKEX ·  Aug 27 09:01

Summary by Moomoo AI

康宁杰瑞制药-B於2024年8月27日進行了股份購回，根據香港聯合交易所有限公司主板上市規則第13.25A條及GEM上市規則第17.27A條的要求，公司已向香港聯交所提交翌日披露報表。報告顯示，公司於2024年8月27日購回了312,000股普通股，每股購回價介於HKD 2.48至HKD 2.53之間，總支付價格為HKD 781,110。購回後，公司的已發行股份減少至964,611,807股，而庫存股份增加至312,000股。該次購回股份將持作庫存股份，並非擬註銷。購回授權於2024年6月12日獲得通過，公司根據該授權可購回的股份總數為96,492,380股。購回後的30天內，即截至2024年9月26日，公司將不會進行任何新股發行或庫存股份再出售或轉讓。執行董事徐霆確認，購回行為符合規定，並無重大變動。
康宁杰瑞制药-B於2024年8月27日進行了股份購回，根據香港聯合交易所有限公司主板上市規則第13.25A條及GEM上市規則第17.27A條的要求，公司已向香港聯交所提交翌日披露報表。報告顯示，公司於2024年8月27日購回了312,000股普通股，每股購回價介於HKD 2.48至HKD 2.53之間，總支付價格為HKD 781,110。購回後，公司的已發行股份減少至964,611,807股，而庫存股份增加至312,000股。該次購回股份將持作庫存股份，並非擬註銷。購回授權於2024年6月12日獲得通過，公司根據該授權可購回的股份總數為96,492,380股。購回後的30天內，即截至2024年9月26日，公司將不會進行任何新股發行或庫存股份再出售或轉讓。執行董事徐霆確認，購回行為符合規定，並無重大變動。
Concord Jerry Pharmaceuticals- B conducted a stock repurchase on August 27, 2024. In accordance with the requirements of Rule 13.25A of the Listing Rules of the Main Board of the Hong Kong Stock Exchange and Rule 17.27A of the GEM Listing Rules, the company has submitted a next-day disclosure report to the Hong Kong Stock Exchange. The report shows that the company repurchased 312,000 ordinary shares on August 27, 2024, with a repurchase price ranging from HKD 2.48 to HKD 2.53 per share, for a total payment of HKD 781,110. After the repurchase, the company's issued shares decreased to 964,611,807 shares, while the treasury shares increased to 312,000 shares. The repurchased shares will be held as treasury shares and not intended for cancellation. The repurchase authorization was obtained on June...Show More
Concord Jerry Pharmaceuticals- B conducted a stock repurchase on August 27, 2024. In accordance with the requirements of Rule 13.25A of the Listing Rules of the Main Board of the Hong Kong Stock Exchange and Rule 17.27A of the GEM Listing Rules, the company has submitted a next-day disclosure report to the Hong Kong Stock Exchange. The report shows that the company repurchased 312,000 ordinary shares on August 27, 2024, with a repurchase price ranging from HKD 2.48 to HKD 2.53 per share, for a total payment of HKD 781,110. After the repurchase, the company's issued shares decreased to 964,611,807 shares, while the treasury shares increased to 312,000 shares. The repurchased shares will be held as treasury shares and not intended for cancellation. The repurchase authorization was obtained on June 12, 2024, and the total number of shares that the company is allowed to repurchase under this authorization is 96,492,380 shares. Within 30 days after the repurchase, until September 26, 2024, the company will not issue any new shares or resell or transfer treasury shares. Executive Director Xu Ting confirmed that the repurchase complies with the regulations and there are no significant changes.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated